BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16339157)

  • 1. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial.
    Ahmed A; Rich MW; Love TE; Lloyd-Jones DM; Aban IB; Colucci WS; Adams KF; Gheorghiade M
    Eur Heart J; 2006 Jan; 27(2):178-86. PubMed ID: 16339157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of serum digoxin concentration and outcomes in patients with heart failure.
    Rathore SS; Curtis JP; Wang Y; Bristow MR; Krumholz HM
    JAMA; 2003 Feb; 289(7):871-8. PubMed ID: 12588271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial.
    Ahmed A; Pitt B; Rahimtoola SH; Waagstein F; White M; Love TE; Braunwald E
    Int J Cardiol; 2008 Jan; 123(2):138-46. PubMed ID: 17382417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of digoxin in reducing one-year mortality in chronic heart failure in the Digitalis Investigation Group trial.
    ; Ahmed A; Waagstein F; Pitt B; White M; Zannad F; Young JB; Rahimtoola SH
    Am J Cardiol; 2009 Jan; 103(1):82-7. PubMed ID: 19101235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations.
    Ahmed A
    J Gerontol A Biol Sci Med Sci; 2007 Mar; 62(3):323-9. PubMed ID: 17389731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure.
    Ahmed A; Gambassi G; Weaver MT; Young JB; Wehrmacher WH; Rich MW
    Am J Cardiol; 2007 Jul; 100(2):280-4. PubMed ID: 17631083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Digoxin Benefit Varies by Risk of Heart Failure Hospitalization: Applying the Tufts MC HF Risk Model.
    Upshaw JN; van Klaveren D; Konstam MA; Kent DM
    Am J Med; 2018 Jun; 131(6):676-683.e2. PubMed ID: 29284111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial.
    Gheorghiade M; Patel K; Filippatos G; Anker SD; van Veldhuisen DJ; Cleland JG; Metra M; Aban IB; Greene SJ; Adams KF; McMurray JJ; Ahmed A
    Eur J Heart Fail; 2013 May; 15(5):551-9. PubMed ID: 23355060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial.
    Ahmed A; Rich MW; Fleg JL; Zile MR; Young JB; Kitzman DW; Love TE; Aronow WS; Adams KF; Gheorghiade M
    Circulation; 2006 Aug; 114(5):397-403. PubMed ID: 16864724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum digoxin concentration and outcomes in women with heart failure: A bi-directional effect and a possible effect modification by ejection fraction.
    Ahmed A; Aban IB; Weaver MT; Aronow WS; Fleg JL
    Eur J Heart Fail; 2006 Jun; 8(4):409-19. PubMed ID: 16311070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.
    Dhaliwal AS; Bredikis A; Habib G; Carabello BA; Ramasubbu K; Bozkurt B
    Am J Cardiol; 2008 Nov; 102(10):1356-60. PubMed ID: 18993155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of digoxin noncompliance on hospitalization and mortality in patients with heart failure in long-term therapy: a prospective cohort study.
    Miura T; Kojima R; Mizutani M; Shiga Y; Takatsu F; Suzuki Y
    Eur J Clin Pharmacol; 2001 Apr; 57(1):77-83. PubMed ID: 11372597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of one-year outcome (death and rehospitalization) in hospitalized heart failure patients with left ventricular ejection fraction >50% versus those with ejection fraction <50%.
    Ezekowitz JA; Lee DS; Tu JV; Newman AM; McAlister FA
    Am J Cardiol; 2008 Jul; 102(1):79-83. PubMed ID: 18572040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.
    Lam PH; Packer M; Gill GS; Wu WC; Levy WC; Zile MR; Brar V; Arundel C; Cheng Y; Singh SN; Allman RM; Fonarow GC; Ahmed A
    Am J Med; 2020 Oct; 133(10):1187-1194. PubMed ID: 32272101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis.
    Adams KF; Patterson JH; Gattis WA; O'Connor CM; Lee CR; Schwartz TA; Gheorghiade M
    J Am Coll Cardiol; 2005 Aug; 46(3):497-504. PubMed ID: 16053964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of digoxin on mortality and morbidity in patients with heart failure.
    Digitalis Investigation Group
    N Engl J Med; 1997 Feb; 336(8):525-33. PubMed ID: 9036306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study.
    Rich MW; McSherry F; Williford WO; Yusuf S;
    J Am Coll Cardiol; 2001 Sep; 38(3):806-13. PubMed ID: 11527638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Digoxin and reduction of heart failure hospitalization in chronic systolic and diastolic heart failure.
    Meyer P; White M; Mujib M; Nozza A; Love TE; Aban I; Young JB; Wehrmacher WH; Ahmed A
    Am J Cardiol; 2008 Dec; 102(12):1681-6. PubMed ID: 19064024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of digoxin in patients with heart failure and reduced ejection fraction according to diabetes status: An analysis of the Digitalis Investigation Group (DIG) trial.
    Abdul-Rahim AH; MacIsaac RL; Jhund PS; Petrie MC; Lees KR; McMurray JJ;
    Int J Cardiol; 2016 Apr; 209():310-6. PubMed ID: 26913372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do evidence-based treatments provide incremental benefits to patients with congestive heart failure already receiving angiotensin-converting enzyme inhibitors? A secondary analysis of one-year outcomes from the Assessment of Treatment with Lisinopril and Survival (ATLAS) study.
    Majumdar SR; McAlister FA; Cree M; Chang WC; Packer M; Armstrong PW;
    Clin Ther; 2004 May; 26(5):694-703. PubMed ID: 15220013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.